Phase 2A, Single Center, Open-label, Single-arm, 24-week Study to Evaluate the Safety, Tolerability and Efficacy of Saroglitazar Magnesium 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (EVIDENCES VIII)
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Saroglitazar (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Acronyms EVIDENCES VIII
- Sponsors Zydus Discovery DMCC
- 04 Jan 2019 Planned initiation date changed from 12 Nov 2018 to 4 Feb 2019.
- 17 Oct 2018 Planned initiation date changed from 23 Aug 2018 to 12 Nov 2018.
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.